Intensive management of dyslipidemia in very high-risk patients with PCSK9 inhibitors
Authors:
Viera Doničová 1; Martina Gáborová 2
Authors place of work:
Diabetologická a metabolická ambulancia, Human-Care s. r. o.
1; Ústav lekárskej fyziológie UPJŠ v Košiciach
2
Published in the journal:
AtheroRev 2019; 4(1): 49-52
Category:
Summary
In the case report on a patient with intolerance of statin therapy and a very high cardiovascular risk, we describe a beneficial effect of the treatment with the lipid profile target values achieved by a monoclonal antibody, the PCSK9 inhibitor.
Keywords:
alirocumab – PCSK9 inhibitor – high cardiovascular risk
Zdroje
- Catapano AL, Graham I, Guy de Backer et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37(39): 2999–3058. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw272>.
- Steinberg D, Witztum JL. Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci USA 2009; 106: 9546–9547. Dostupné z DOI: <http://dx.doi.org/10.1073/pnas.0904560106>.
- Gearing ME. A potential new weapon aginst heart disease: PCSK9 inhibitors. Science in the News 2015. Harvard University. Dostupné z WWW: <http://sitn.hms.harvard.edu/flash/2015/a-potential-new-weapon-against-heart-disease-pcsk9-inhibitors/>.
- Li C, Lin L, Zhang W et al. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. J Am Heart Assoc 2015; 4(6): e001937. Dostupné z DOI: <http://dx.doi.org/10.1161/JAHA.115.001937>.
- Janský P, Roslová H, Vrablík M. 2016 ESC/EAS Guidelines for the management of dyslipidaemias: Summary of the document prepared by the Czech Society of Cardiology. Cor Vasa 2017; 59(4): e389–e415. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crvasa.2017.03.007>.
- Vrablík M. Novinky v kardiovaskulární prevenci: od guidelines k novým léčebným možnostem. Interní Med Praxi 2015; 17(5): 233–238.
Štítky
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsČlánok vyšiel v časopise
Athero Review
2019 Číslo 1
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- Nutraceuticals with hypolipidemic effect in clinical practice: a summary statement of the International expert panel of lipidologists prepared by the committee of the Czech society for atherosclerosis
- Lysosomal acid lipase deficiency in differential diagnosis of familial hypercholesterolemia
- Therapy of dyslipidaemia in patient with muscular dystrophy: case report
- Psoriasis as a risk factor for cardiovascular events: case report